FDA Warning Letter on cGMP Violations of Over-the-Counter Drug Manufacturer
A prominent manufacturer of over-the-counter drug products, was recently issued a detailed FDA warning letter (#663478) for a number of cGMP violations, including: Insufficient Verification of Component Identity The company failed to conduct necessary tests to confirm the identity of each component used in drug products, including high-risk components like glycerin and propylene glycol, which…